In the battle against cancer, AREVA Med is glad to announce the “public hearing” period for the construction of AREVA Med’s new lead-212 isotopes production facility was successfully completed on March 15, 2011. We are now on the threshold of constructing this unique facility at AREVA’s Bessines site in the Limousin region of France.
AREVA Med, an AREVA subsidiary, is dedicated to developing medical grade lead-212 isotopes to be used in promising radioimmunotherapy (RIT). Lead-212 is a rare radioactive isotope that lies at the heart of promising nuclear medical research to develop new cancer treatments.
In nuclear medicine, the development of new treatments is dictated by isotope availability. By utilizing AREVA’s engineering and technical expertise, in March 2010, AREVA Med announced the construction of a Lead-212 industrial production plant that will allow the creation of new targeted therapies for patients.
In August 2010, AREVA Med formed an Advisory Committee to provide strategic advice and scientific guidance in the field of Radioimmunotherapy.
Tags: AREVA Med